促红细胞生成素在贫血治疗中的应用进展及市场简析

Characteristics,clinical use and market analysis of currently available erythropoietins for the therapy of anemia

自从第一个促红细胞生成素(erythropoietin,EPO)药物于1988年上市,迄今已超过30年时间,本类药物在贫血治疗中的有效性和安全性已经过广泛验证,2017年度国际总销售额超过55亿美元。本文就当前国际和国内主要EPO类已上市药物的特点、适应证及使用方式、有效性及安全性、市场情况及趋势等进行了总结和简要分析,显示EPO类药物治疗贫血安全有效,长效EPO品种已逐步取代短效EPO品种成为国际市场主流,而国内虽然尚无长效EPO品种上市,但在未来3~5年将陆续有国产长效EPO品种投放市场。

Since the approval of Epogen in 1988,erythropoietin(EPO)-based recombinant protein agents have been used for the therapy of anemia for over thirty years.In this context,we briefly introduce and summarize the characteristics,indications,efficacy and safety profiles of EPO-based recombinant protein agents currently available on the market,and make a brief analysis to estimate the market trend in the near future.In summary,EPO-based recombinant protein agents have the ability to correct anemia with controlled safety concerns.At the same time,instead of EPOs with short-term effects,EPOs with longer half-lives have occupied the majority of international market shares.